Divi's Laboratories Limited — Others, 11-08-2025: Shareholders meeting

Divi's Laboratories shareholders approved all resolutions at the 35th Annual General Meeting. For the financial year ended March 31, 2025, the company reported a consolidated total income of ₹9,712 Cr, Profit Before Tax (PBT) of ₹2,916 Cr, and Profit After Tax (PAT) of ₹2,191 Cr. The board approved a dividend of ₹30 per equity share. Operationally, the new Unit-3 Kakinada facility began commercial production, boosting backward integration. The company also saw increased activity in its Custom Synthesis segment and continues to strengthen its peptide API capabilities. For the quarter ended June 30, 2025, consolidated total income was ₹2,529 Cr, PBT ₹733 Cr, and PAT ₹545 Cr.